GMP violations prompt U.S. FDA warning against 2 Indian drugmakers

08/25/2013 | Economic Times (India), The

Indian drugmakers Posh Chemicals and Promed Exports received warning letters from the U.S. FDA that indicated breaches in good manufacturing practices. Six India-based drug facilities have received the notices in the past three months. Lupin Pharma CEO Vinita Gupta said "all the FDA is trying to do is differentiate the good manufacturers from the not-so-good ones. Indian manufacturers are not being targeted."

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC